Phase 1a/1b Study of IGM-8444 Alone and in Combination in Subjects With Relapsed, Refractory, or Newly Diagnosed Cancers

Key Inclusion Criteria:

Age ≥ 18 years at time of signing ICF
ECOG Performance Status of 0 or 1
Histologic documentation of incurable, locally advanced or metastatic tumor of the type being evaluated in individual cohorts.
Adequate hepatic and renal function and adequate bone marrow reserve function
For combination cohorts, patients must be eligible to receive the chemotherapy or targeted agent.
Ph1a only: No more than three prior therapeutic regimens
Ph1b only: FOLFIRI naive subjects that received no more than 1 prior therapeutic regimen administered for the treatment of cancer in the advanced/metastatic setting

Key Exclusion Criteria:

Inability to comply with study and follow-up procedures.
Prior DR5 agonist therapy.
Concomitant use of agents well-known to cause liver toxicity.
Concomitant use of anti-cancer agents
Palliative radiation to bone metastases within 2 weeks prior to Day 1.
Major surgical procedure within 4 weeks prior to Day 1.
Untreated or active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control). Patients with a history of treated CNS metastases are eligible.
Prior use of any chemotherapeutic agent or small molecule inhibitors (SMI) within 2 weeks or 5 half-lives, prior to the first dose of study treatment
Treatment with a monoclonal antibody, or any other anticancer agent (including biologic, experimental, or hormonal therapy) investigational or otherwise, that is not chemotherapy or a SMI, within 4 weeks or five half-lives prior to first dose of study treatment.
Ph1b: Subjects who have previously received FOLFIRI treatment for advanced or metastatic disease